Phase I study of vemurafenib in children with recurrent or progressive BRAFV600E mutant brain tumors: Pacific Pediatric Neuro-Oncology Consortium study (PNOC-002).

Oncotarget
Theodore NicolaidesMichael Prados

Abstract

Background: BRAFV600E mutation is present in a subset of pediatric brain tumors. Vemurafenib is an oral, selective ATP-competitive inhibitor of BRAFV600E kinase. The goal of this multi-center study conducted through the Pacific Pediatric Neuro-Oncology Consortium (PNOC) was to determine the recommended phase 2 dose (RP2D) and dose limiting toxicities (DLTs) in children < 18 years with recurrent or progressive BRAFV600E mutant brain tumors. Results: Nineteen eligible patients were enrolled. Eleven patients had received three or more prior therapies. Data reported are from the start of treatment for the first patient (April 30 2014) through August 31 2019. The RP2D was defined as 550 mg/m2 twice daily after DLT criteria adjustment for rash. Related grade ≥ 3 adverse events included secondary keratoacanthoma (n = 1); rash (n =16); and fever (n = 5). Subjects received a median of 23 cycles (range 3-63). Four patients remain on treatment. Centrally reviewed best radiographic responses included 1 complete response, 5 partial responses, and 13 stable disease. The steady-state area under the curve (AUC0-∞median) was 604 mg*h/L (range 329-1052). Methods: Vemurafenib was given starting at 550 mg/m2, twice daily which corresponds to the a...Continue Reading

References

Jun 18, 2002·Nature·Helen DaviesP Andrew Futreal
Jun 9, 2007·Biochimica Et Biophysica Acta·Deborah T LeichtGuri Tzivion
Mar 17, 2010·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Patrick Y WenSusan M Chang
Sep 8, 2010·The New England Journal of Medicine·Keith T FlahertyPaul B Chapman
Nov 1, 2011·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Theodore P NicolaidesC David James
Mar 28, 2013·Proceedings of the National Academy of Sciences of the United States of America·Angela J SievertAdam C Resnick
Jan 1, 2012·CPT: Pharmacometrics & Systems Pharmacology·D R Mould, R N Upton
May 8, 2014·Neuro-oncology·Matthias A KarajannisJeffrey C Allen
Aug 26, 2016·Nature Communications·Patrizia CammareriGareth J Inman
Mar 17, 2018·Seminars in Neurology·Mariella G Filbin, Dominik Sturm
Sep 12, 2019·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Mark W KieranJames A Whitlock
Sep 13, 2019·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Jean DonadieuSébastien Héritier

❮ Previous
Next ❯

Citations

Mar 7, 2021·Cancers·Yusuke FunakoshiMasahiro Mizoguchi
Apr 18, 2021·Child's Nervous System : ChNS : Official Journal of the International Society for Pediatric Neurosurgery·Juan Pablo Muñoz PérezAndrés Morales La Madrid
Jun 12, 2021·Seminars in Cancer Biology·Mirjam Blattner-JohnsonElke Pfaff
Jul 4, 2021·Neurologic Clinics·Fatema Malbari
Aug 27, 2021·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Karisa C SchreckJean M Mulcahy Levy

❮ Previous
Next ❯

Methods Mentioned

BETA
surgical resection
xenografts
biopsy
genotyping

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.